RxDoctor Payments DataLook up a doctor →

Joshua Buck, NP

Family · Johnson City, TNNPI 1205357977

Payments from drug & device makers

$19,065in general payments, 2019–2025

Across 866 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • AstraZeneca$2K
  • Johnson & Johnson$1K
  • Merck$1K
  • E.r. Squibb & Sons, L.L.C.$793
  • Incyte Corporation$706
  • plus $11K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis70$2,512
AstraZeneca(2 entities)77$1,568
Johnson & Johnson50$1,030
Merck49$1,015
E.r. Squibb & Sons, L.L.C.53$793
Incyte Corporation29$706
Astellas Pharma US Inc32$703
Pfizer32$697
Daiichi Sankyo Inc.30$641
Bristol Myers Squibb36$614
AVEO Pharmaceuticals, Inc.14$553
Gilead(2 entities)24$540
Amgen22$488
Lilly USA, LLC23$466
Genentech USA, Inc.22$446
Seagen Inc.16$438
GSK24$405
AbbVie25$392
Sanofi17$371
Eisai Inc.17$327
Takeda Pharmaceuticals U.S.A., Inc.14$300
Sanofi-aventis U.S. LLC4$300
Regeneron Healthcare Solutions, Inc.10$277
Exelixis Inc.9$251
Bayer10$186
Ipsen Biopharmaceuticals, Inc8$186
EMD Serono, Inc.8$178
Puma Biotechnology, Inc.9$161
Tersera Therapeutics LLC8$155
Rigel Pharmaceuticals, Inc.7$146
Pharmacyclics LLC, An Abbvie Company7$134
Beigene USA, Inc.6$132
Genmab U.S., Inc.5$117
Array Biopharma Inc5$113
Novo Nordisk13$112
Deciphera Pharmaceuticals Inc.4$108
Biohaven Pharmaceuticals, Inc.7$102
Karyopharm Therapeutics Inc.4$100
Beone Medicines USA, Inc.5$98
Boehringer Ingelheim5$95
Myriad Genetic Laboratories, Inc.5$90
Morphosys, US Inc.3$88
G1 Therapeutics, Inc.4$73
Mirati Therapeutics, Inc.2$66
Caris MPI, Inc.3$60
Geron Corporation3$58
Taiho Oncology, Inc.3$55
Pharmaessentia USA Corporation2$50
Jazz Pharmaceuticals Inc.2$45
Iovance Biotherapeutics, Inc.2$44
Epizyme, Inc.2$41
Apellis Pharmaceuticals, Inc.2$41
Kyowa Kirin, Inc.2$37
Sobi, Inc2$33
Dexcom, Inc.2$33
Agios Pharmaceuticals, Inc.2$31
Celltrion USA Inc.1$29
Foundation Medicine, Inc.1$27
Alnylam Pharmaceuticals Inc.1$26
Acceleron Pharma, Inc.2$26

How this compares

$19,065 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee →

Medicare billing

Part B allowed, 2024
$218,886
Medicare patients
76
Services billed
9,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Johnson City

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →